Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.

J. H. Lipton, P. Bryden, M. K. Sidhu, H. Huang, L. J. McGarry, S. Lustgarten, S. Mealing, B. Woods, J. Whelan, N. Hawkins

Research output: Contribution to journalArticlepeer-review


We compared the efficacy of ponatinib and second-generation tyrosine kinase inhibitors (2G-TKIs: bosutinib, dasatinib, and nilotinib) in chronic phase CML resistant/intolerant to ≥1 prior 2G-TKI. Estimated probabilities of CCyR with 2G-TKI ranged from 22% to 26%, compared with 60% (95% CrI 52–68%) with ponatinib. The estimated probability of ponatinib providing higher response rate than all other included treatments was 99% (CCyR) and 97% (MCyR). Use of further 2G-TKI may provide limited benefit in CP-CML patients resistant/intolerant to prior 2G-TKI treatment. Compared with 2G-TKIs, ponatinib is estimated to provide substantially higher probability of achieving CCyR and MCyR; safety was not compared.
Original languageEnglish
Pages (from-to)58-64
Number of pages7
JournalLeukemia research
Issue number1
Early online date1 Nov 2014
Publication statusPublished - Jan 2015


  • CML
  • Ponatinib
  • Second-generation tyrosine kinase inhibitor
  • Response
  • Systematic review

Cite this